Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

RVX_Anonymous

Jun 01, 2023 04:11PM

jonzobot

Rank: President [?]

Points: 2527 [?]

Votes: 20 Score: 3.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

in response to

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

RVX_Anonymous

posted on Jun 01, 2023 07:24PM

Two patients?

I mean, that's great but hardly meaningful in a statistical sense.

2 Recommendations

Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

KOO-KOO2

Jun 02, 2023 07:38AM

Reply New Message

Back To Forum List View

Please to post a reply